LAS VEGAS—Whoop gained traction as a performance wearable used by elite athletes, professional teams and Olympians to track physiological strain and sleep.
The company has evolved into a broader clinical and digital health platform that layers medical-grade hardware, blood diagnostics, electronic health record (EHR) syncing, and physician care on top of its continuous biometric tracking. The company's FDA-cleared ECG detects signs of atrial fibrillation and allows members to share results with their healthcare provider.
Whoop is a screenless, wrist-worn device that measures strain, recovery and sleep 24/7, paired with Whoop Coach, an AI-powered, in-app health and fitness assistant. The company expanded its Advanced Labs testing—combining Quest blood testing, clinician reviews and AI insights—to non-members, alongside integrating Grail's multi-cancer early detection test. Whoop partners with health platform HealthEx to let users connect their medical records directly to the Whoop app, combining medical history with biometric data. A feature rolled out earlier this year lets Whoop members directly connect with clinicians through the app, including live, on-demand video consultations.
The company has raised over $900 million to date, including a $575 million series G round in March, pushing its valuation to $10 billion. Whoop told Bloomberg it plans to hire 600 people this year, a roughly 75% boost to its headcount, as it works to further integrate AI into its health and wellness monitoring tools and to expand internationally. The company is on track for an initial public offering in 18 months, executives told Bloomberg in August.
The company is positioning itself as a continuous health monitor that goes beyond fitness tracking.
Source link







